Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency

被引:0
|
作者
Budhipramono, Albert [1 ]
Sharma, Ruchika [2 ,3 ]
Wysocki, Christian Allen [2 ,4 ]
Zia, Ayesha N. [2 ,3 ]
Adkins, Brian D. [1 ,2 ]
机构
[1] Univ Texas Southwestern Med Ctr, Dept Pathol, Dallas, TX 75390 USA
[2] Childrens Hlth Syst, Dallas, TX 75235 USA
[3] Univ Texas Southwestern Med Ctr, Dept Pediat, Div Hematol & Oncol, Dallas, TX USA
[4] Univ Texas Southwestern Med Ctr, Dept Pediat, Div Allergy & Immunol, Dallas, TX USA
关键词
common variable immunodeficiency; pediatric apheresis; thrombotic thrombocytopenic purpura; CAPLACIZUMAB; SCORE; MICROANGIOPATHY; DEFICIENCY; RITUXIMAB; ANTIBODY; REGISTRY; TTP;
D O I
10.1002/jca.22154
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Common variable immunodeficiency (CVID) is a disorder characterized by hypogammaglobulinemia resulting in recurrent infections. While autoimmune disorders are common in patients with CVID, no association has been reported between CVID and immune thrombotic thrombocytopenic purpura (iTTP), a disorder most often caused by autoantibodies that compromise the activity of the enzyme ADAMTS13. Reduced ADAMTS13 activity results in the accumulation of large von Willebrand factor multimers that can consume platelets and cause microvascular thrombosis and organ injury, ultimately resulting in mortality in most cases of untreated iTTP. Here, we report a 12-year-old male with CVID who developed iTTP, underwent therapeutic plasma exchange (TPE), and subsequently recovered. We conducted a systematic review for other cases of CVID co-occurring with iTTP and present additional cases of this rare presentation. We highlight the importance of prompt recognition of iTTP in a patient with CVID and timely initiation of TPE.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Unusual Presentation of Thrombotic Thrombocytopenic Purpura in a Newly Diagnosed Pediatric Patient With Systemic Lupus Erythematosus in the Setting of MIS-C
    Al-Antary, Eman T.
    Arar, Rewa
    Persaud, Yogindra
    Fathalla, Basil M.
    Rajpurkar, Madhvi
    Bhambhani, Kanta
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (03) : E812 - E815
  • [42] Therapeutic plasma exchange plus corticosteroid for the treatment of the thrombotic thrombocytopenic purpura: A single institutional experience in the southern Marmara region of Turkey
    Ozkalemkas, Fahir
    Ali, Ridvan
    Ozkocaman, Vildan
    Ozcelik, Tulay
    Ozkan, Atilla
    Tunali, Ahmet
    TRANSFUSION AND APHERESIS SCIENCE, 2007, 36 (01) : 109 - 115
  • [43] Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
    Michinori Kayashima
    Kazuya Sakai
    Kazuki Harada
    Jun Kanetake
    Masayuki Kubo
    Eriko Hamada
    Masaki Hayakawa
    Kinta Hatakeyama
    Masanori Matsumoto
    International Journal of Hematology, 2021, 114 : 415 - 423
  • [44] Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated with Human Immunodeficiency Virus Failing Extensive Treatment with Plasma Exchange: A Report of Two Cases
    Evans, Michael W.
    Vaughan, Leroy B.
    Giffi, Victoria S.
    Zimrin, Ann B.
    Hess, John R.
    AIDS PATIENT CARE AND STDS, 2010, 24 (06) : 349 - 352
  • [45] THERAPEUTIC PLASMA-EXCHANGE DOES NOT APPEAR TO BE EFFECTIVE IN THE MANAGEMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC-UREMIC SYNDROME FOLLOWING BONE-MARROW TRANSPLANTATION
    SARODE, R
    MCFARLAND, JG
    FLOMENBERG, N
    CASPER, JT
    COHEN, EP
    DROBYSKI, WR
    ASH, RC
    HOROWITZ, MM
    CAMITTA, B
    LAWTON, C
    GARBRECHT, F
    GOTTSCHALL, JL
    BONE MARROW TRANSPLANTATION, 1995, 16 (02) : 271 - 275
  • [46] United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange
    Bandarenko, N
    Brecher, ME
    JOURNAL OF CLINICAL APHERESIS, 1998, 13 (03) : 133 - 141
  • [47] Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression - report of two cases
    Starck, M
    Abedinpour, F
    Dendorfer, U
    Wagner-Czekalla, J
    Pachmann, M
    Mann, JF
    Nerl, C
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (05) : 436 - 440
  • [48] Rituximab and Intermediate-Purity Plasma-Derived Factor VIII Concentrate (Koate®) as Adjuncts to Therapeutic Plasma Exchange For Thrombotic Thrombocytopenic Purpura in Patients With an ADAMTS13 Inhibitor
    Pandey, Soumya
    Nakagawa, Mayumi
    Rosenbaum, Eric R.
    Arnaoutakis, Konstantinos
    Hutchins, Laura F.
    Makhoul, Issam
    Milojkovic, Natasha
    Cottler-Fox, Michele
    JOURNAL OF CLINICAL APHERESIS, 2015, 30 (01) : 50 - 54
  • [49] Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange
    Peedin, Alexis R.
    Park, Yara A.
    Mazepa, Marshall A.
    Rollins-Raval, Marian A.
    Brecher, Mark E.
    Raval, Jay S.
    THERAPEUTIC APHERESIS AND DIALYSIS, 2018, 22 (06) : 662 - 665
  • [50] Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: Short heparin-free hemodialysis helps to attenuate citrate load
    Buturovic-Ponikvar, J
    Pernat, AM
    Ponikvar, R
    THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (03) : 258 - 261